Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

The company is paying $350 million upfront, and potentially $1.2 billion overall, for a radiopharmaceutical for prostate ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, ...

On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu ...

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...